STOCK TITAN

[Form 4] NATIONAL RESEARCH CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

National Research Corp (NRC) reported a director equity grant. On 10/17/2025, a Director received a Director Stock Option (Right to Buy) for 22,625 shares at an exercise price of $11.61, expiring on 10/17/2035. The transaction was coded “A” (grant) and recorded as direct ownership.

The award was made under the company’s 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.

National Research Corp (NRC) ha riferito una concessione di azioni a favore di un direttore. Il 17/10/2025, un Direttore ha ricevuto una Stock Option per Direttore (Diritto di Acquisto) per 22.625 azioni a un prezzo di esercizio di $11,61, con scadenza il 17/10/2035. La transazione è stata codificata come “A” (concessione) e registrata come proprietà diretta.

La concessione è stata effettuata ai sensi del piano Omnibus Incentive 2025 della società per la partecipazione a due riunioni in presenza nel 2025.

National Research Corp (NRC) informó una asignación de acciones para directores. El 17/10/2025, un Director recibió una Opción de Acciones para Director (Derecho de Compra) por 22,625 acciones a un precio de ejercicio de $11.61, con vencimiento el 17/10/2035. La transacción se codificó como “A” (concesión) y registrada como propiedad directa.

La adjudicación se realizó bajo el plan 2025 Omnibus Incentive Plan de la empresa para participar en dos reuniones presenciales durante 2025.

National Research Corp (NRC)는 이사 보상으로 주식 부여를 보고했습니다. 2025년 10월 17일 이사에게 22,625주에 대해 행사 가격 $11.61로 주식매수선택권(주식매수권)이 부여되었으며 만기는 2035년 10월 17일입니다. 거래는 “A”(부여)로 코딩되었고 직접 소유로 기록되었습니다.

이번 수상은 2025년 Omnibus Incentive Plan에 따라 2025년 두 차례의 대면 회의 참석에 대해 이루어졌습니다.

National Research Corp (NRC) a annoncé une attribution d’actions à un administrateur. Le 17/10/2025, un Directeur a reçu une Option d’Achat d’Actions (Droit d’Acheter) pour 22 625 actions à un prix d’exercice de 11,61 $, expirant le 17/10/2035. La transaction a été codée « A » (attribution) et enregistrée comme propriété directe.

L’attribution a été effectuée dans le cadre du Plan Omnibus d’Incitations 2025 de l’entreprise pour la participation à deux réunions en personne au cours de 2025.

National Research Corp (NRC) meldete eine Direktorbeteiligung. Am 17.10.2025 erhielt ein Direktor eine Direktoraktieoption (Kaufrecht) über 22.625 Aktien zu einem Ausübungspreis von 11,61 USD, mit Ablauf am 17.10.2035. Die Transaktion wurde als „A“ (Zuwendung) codiert und als direkter Eigentumseffekt verbucht.

Der Zuschuss wurde im Rahmen des Unternehmens 2025 Omnibus Incentive Plan gewährt, für die Teilnahme an zwei persönlichen Meetings im Jahr 2025.

أعلنت National Research Corp (NRC) عن منح أسهم لمتحدث/director. في 17/10/2025، تلقى مدير خيار أسهم مدير (حق الشراء) لــ 22,625 سهماً بسعر تنفيذ 11.61 دولاراً، ينتهي في 17/10/2035. تمت ترميز المعاملة كـ “A” (منحة) وتسجيلها كملكية مباشرة.

تم منح الجائزة وفق خطة الحوافز الشاملة 2025 للشركة للمشاركة في اجتماعَين حضورياً خلال 2025.

National Research Corp (NRC) 报告了一项董事的股票授予。 2025/10/17,董事获得了董事股票期权(买入权),数量为22,625股,行使价格为11.61美元,有效期至2035/10/17。该交易被编码为“A”(授予)并登记为直接持有。

该奖励是在公司2025年综合激励计划下,为参加2025年的两次现场会议而授予。

Positive
  • None.
Negative
  • None.

National Research Corp (NRC) ha riferito una concessione di azioni a favore di un direttore. Il 17/10/2025, un Direttore ha ricevuto una Stock Option per Direttore (Diritto di Acquisto) per 22.625 azioni a un prezzo di esercizio di $11,61, con scadenza il 17/10/2035. La transazione è stata codificata come “A” (concessione) e registrata come proprietà diretta.

La concessione è stata effettuata ai sensi del piano Omnibus Incentive 2025 della società per la partecipazione a due riunioni in presenza nel 2025.

National Research Corp (NRC) informó una asignación de acciones para directores. El 17/10/2025, un Director recibió una Opción de Acciones para Director (Derecho de Compra) por 22,625 acciones a un precio de ejercicio de $11.61, con vencimiento el 17/10/2035. La transacción se codificó como “A” (concesión) y registrada como propiedad directa.

La adjudicación se realizó bajo el plan 2025 Omnibus Incentive Plan de la empresa para participar en dos reuniones presenciales durante 2025.

National Research Corp (NRC)는 이사 보상으로 주식 부여를 보고했습니다. 2025년 10월 17일 이사에게 22,625주에 대해 행사 가격 $11.61로 주식매수선택권(주식매수권)이 부여되었으며 만기는 2035년 10월 17일입니다. 거래는 “A”(부여)로 코딩되었고 직접 소유로 기록되었습니다.

이번 수상은 2025년 Omnibus Incentive Plan에 따라 2025년 두 차례의 대면 회의 참석에 대해 이루어졌습니다.

National Research Corp (NRC) a annoncé une attribution d’actions à un administrateur. Le 17/10/2025, un Directeur a reçu une Option d’Achat d’Actions (Droit d’Acheter) pour 22 625 actions à un prix d’exercice de 11,61 $, expirant le 17/10/2035. La transaction a été codée « A » (attribution) et enregistrée comme propriété directe.

L’attribution a été effectuée dans le cadre du Plan Omnibus d’Incitations 2025 de l’entreprise pour la participation à deux réunions en personne au cours de 2025.

National Research Corp (NRC) meldete eine Direktorbeteiligung. Am 17.10.2025 erhielt ein Direktor eine Direktoraktieoption (Kaufrecht) über 22.625 Aktien zu einem Ausübungspreis von 11,61 USD, mit Ablauf am 17.10.2035. Die Transaktion wurde als „A“ (Zuwendung) codiert und als direkter Eigentumseffekt verbucht.

Der Zuschuss wurde im Rahmen des Unternehmens 2025 Omnibus Incentive Plan gewährt, für die Teilnahme an zwei persönlichen Meetings im Jahr 2025.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wheeler Penny Ann

(Last) (First) (Middle)
C/O NATIONAL RESEARCH CORPORATION
1245 Q STREET

(Street)
LINCOLN NE 68508

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NATIONAL RESEARCH CORP [ NRC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy)(1) $11.61 10/17/2025 A 22,625 10/17/2025 10/17/2035 Common Stock 22,625 $0 22,625 D
Explanation of Responses:
1. This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.
/s/ Penny Ann Wheeler, by Heidi Hornung-Scherr, attorney-in-fact, pursuant to a POA previously filed with the SEC 10/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NRC disclose on Form 4?

A Director received a grant of options for 22,625 shares at an exercise price of $11.61, expiring 10/17/2035.

What is the transaction date for the NRC Form 4?

The transaction date is 10/17/2025.

What was the purpose of the option grant at NRC (NRC)?

It was awarded under the 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.

What is the ownership form after the grant for NRC’s director?

The options are reported as Direct (D) ownership.

What was the Form 4 transaction code?

The filing lists transaction code A, indicating a grant of derivative securities.

How many derivative securities are beneficially owned after the NRC grant?

The director beneficially owns 22,625 derivative securities following the reported transaction.
National Resh Corp

NASDAQ:NRC

NRC Rankings

NRC Latest News

NRC Latest SEC Filings

NRC Stock Data

275.15M
12.09M
46.42%
51.54%
1.62%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States
LINCOLN